FindTrial
Sign In

Pharmacogenetic of methotrexate and establishment of personalised treatment for rheumatoid arthritis.

Pharmacogenetic of methotrexate and establishment of personalised treatment for rheumatoid arthritis. - Pharmacogenetic of methotrexate and establishment of personalised treatment for rheumatoid arthritis.

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000055177
Enrollment
600
Registered
2024-08-06
Start date
2023-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Sponsors

Keio University School of medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients participating in the "Pharmacogenetics and Pharmacokinetics of Methotrexate in Japanese Patients with Rheumatoid Arthritis study"(20130405) and the "Establishment of Personalised Therapy with Methotrexate in Rheumatoid Arthritis study."(20140445)

Exclusion criteria

Exclusion criteria: Ineligible for the study judged by physicians

Design outcomes

Primary

MeasureTime frame
Association of MTX-PG concentrations and drug-metabolising enzyme gene polymorphisms with efficacy and safety indicators.—

Countries

Japan

Contacts

Public ContactYuko Kaneko

Keio University School of Medicine Division of Rheumatology

ykaneko.z6@keio.jp03-5363-3786

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026